ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "e12adbbd-f350-446c-b98f-4cf79b1df4d6"}, "_deposit": {"created_by": 19, "id": "4775", "owners": [19], "pid": {"revision_id": 0, "type": "depid", "value": "4775"}, "status": "published"}, "_oai": {"id": "oai:air.repo.nii.ac.jp:00004775", "sets": ["1369"]}, "author_link": ["14147", "14158", "14149", "14152", "14148", "14156", "14150", "14145", "14159", "14157", "14146", "14154", "14155", "14153", "14151"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-06-30", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "30", "bibliographicPageStart": "21", "bibliographicVolumeNumber": "47", "bibliographic_titles": [{"bibliographic_title": "秋田医学"}]}]}, "item_10001_description_5": {"attribute_name": "内容記述(抄録)", "attribute_value_mlt": [{"subitem_description": "Objective : We conducted a multicenter study in Akita Prefecture, Japan, to characterize the efficacy and safety of sofosbuvir (SOF) plus ribavirin (RBV) therapy in Japanese patients infected with hepatitis C virus (HCV) genotype 2.\nMethods : All of the patients were infected with HCV genotype 2. Patients received 12 weeks of treatment with 400 mg of SOF daily plus weight-based RBV (600-1,000 mg daily).\nResults : A total of 170 patients were enrolled in this study, and 167 patients were followed for 12 weeks after its completion. Among our patients, 28.2% (48/170) had liver cirrhosis (LC). Overall, 159 patients achieved a sustained virologic response for 12 weeks (SVR12), while 8 showed virologic failure. There were no significant differences in the rates of SVR12 between the chronic hepatitis (CH) and LC patients. No significant differences were noted between the CH and LC patients in the rates of any adverse events.\nConclusion : We found that SOF plus RBV treatment resulted in high rates of SVR12 with a favorable safety and tolerability profile, including patients with cirrhosis.", "subitem_description_type": "Other"}]}, "item_10001_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.20569/00005119", "subitem_identifier_reg_type": "JaLC"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "秋田医学会"}]}, "item_10001_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00009294", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0386-6106", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Matsuzawa, Hisanori"}], "nameIdentifiers": [{"nameIdentifier": "14145", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohshima, Shigetoshi"}], "nameIdentifiers": [{"nameIdentifier": "14146", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Goto, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "14147", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Komatsu, Masafumi"}], "nameIdentifiers": [{"nameIdentifier": "14148", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakane, Kunio"}], "nameIdentifiers": [{"nameIdentifier": "14149", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yagisawa, Hitoshi"}], "nameIdentifiers": [{"nameIdentifier": "14150", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakajima, Kou"}], "nameIdentifiers": [{"nameIdentifier": "14151", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hoshino, Takao"}], "nameIdentifiers": [{"nameIdentifier": "14152", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuramitsu, Tomoyuki"}], "nameIdentifiers": [{"nameIdentifier": "14153", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoneyama, Kazuo"}], "nameIdentifiers": [{"nameIdentifier": "14154", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujishima, Yuukou"}], "nameIdentifiers": [{"nameIdentifier": "14155", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Watanabe, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "14156", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kataoka, Ei"}], "nameIdentifiers": [{"nameIdentifier": "14157", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Segawa, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "14158", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iijima, Katsunori"}], "nameIdentifiers": [{"nameIdentifier": "14159", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-08-28"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "akitai47_1(21).pdf", "filesize": [{"value": "631.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 631400.0, "url": {"label": "akitai47_1(21)", "url": "https://air.repo.nii.ac.jp/record/4775/files/akitai47_1(21).pdf"}, "version_id": "24205bca-349b-445e-bff7-cb31fbe4b424"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Hepatitis C", "subitem_subject_scheme": "Other"}, {"subitem_subject": "genotype2", "subitem_subject_scheme": "Other"}, {"subitem_subject": "sofosbuvir", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ribavirin", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "EFFICACY AND SAFETY OF TREATMENT WITH SOFOSBUVIR PLUS RIBAVIRIN FOR HEPATITS C VIRUS GENOTYPE2", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "EFFICACY AND SAFETY OF TREATMENT WITH SOFOSBUVIR PLUS RIBAVIRIN FOR HEPATITS C VIRUS GENOTYPE2"}]}, "item_type_id": "10001", "owner": "19", "path": ["1369"], "permalink_uri": "https://doi.org/10.20569/00005119", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-08-28"}, "publish_date": "2020-08-28", "publish_status": "0", "recid": "4775", "relation": {}, "relation_version_is_last": true, "title": ["EFFICACY AND SAFETY OF TREATMENT WITH SOFOSBUVIR PLUS RIBAVIRIN FOR HEPATITS C VIRUS GENOTYPE2"], "weko_shared_id": -1}
  1. 20 医学部:School of Medicine
  2. 20C 本学関連学会刊行誌
  3. 20C1 秋田医学
  4. 第47巻1号

EFFICACY AND SAFETY OF TREATMENT WITH SOFOSBUVIR PLUS RIBAVIRIN FOR HEPATITS C VIRUS GENOTYPE2

https://doi.org/10.20569/00005119
https://doi.org/10.20569/00005119
1a2e82cb-343a-420f-86b0-1000af124c84
名前 / ファイル ライセンス アクション
akitai47_1(21).pdf akitai47_1(21) (631.4 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2020-08-28
タイトル
タイトル EFFICACY AND SAFETY OF TREATMENT WITH SOFOSBUVIR PLUS RIBAVIRIN FOR HEPATITS C VIRUS GENOTYPE2
言語
言語 eng
キーワード
主題Scheme Other
主題 Hepatitis C
キーワード
主題Scheme Other
主題 genotype2
キーワード
主題Scheme Other
主題 sofosbuvir
キーワード
主題Scheme Other
主題 ribavirin
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
ID登録
ID登録 10.20569/00005119
ID登録タイプ JaLC
著者 Matsuzawa, Hisanori

× Matsuzawa, Hisanori

WEKO 14145

Matsuzawa, Hisanori

Search repository
Ohshima, Shigetoshi

× Ohshima, Shigetoshi

WEKO 14146

Ohshima, Shigetoshi

Search repository
Goto, Takashi

× Goto, Takashi

WEKO 14147

Goto, Takashi

Search repository
Komatsu, Masafumi

× Komatsu, Masafumi

WEKO 14148

Komatsu, Masafumi

Search repository
Nakane, Kunio

× Nakane, Kunio

WEKO 14149

Nakane, Kunio

Search repository
Yagisawa, Hitoshi

× Yagisawa, Hitoshi

WEKO 14150

Yagisawa, Hitoshi

Search repository
Nakajima, Kou

× Nakajima, Kou

WEKO 14151

Nakajima, Kou

Search repository
Hoshino, Takao

× Hoshino, Takao

WEKO 14152

Hoshino, Takao

Search repository
Kuramitsu, Tomoyuki

× Kuramitsu, Tomoyuki

WEKO 14153

Kuramitsu, Tomoyuki

Search repository
Yoneyama, Kazuo

× Yoneyama, Kazuo

WEKO 14154

Yoneyama, Kazuo

Search repository
Fujishima, Yuukou

× Fujishima, Yuukou

WEKO 14155

Fujishima, Yuukou

Search repository
Watanabe, Daisuke

× Watanabe, Daisuke

WEKO 14156

Watanabe, Daisuke

Search repository
Kataoka, Ei

× Kataoka, Ei

WEKO 14157

Kataoka, Ei

Search repository
Segawa, Daisuke

× Segawa, Daisuke

WEKO 14158

Segawa, Daisuke

Search repository
Iijima, Katsunori

× Iijima, Katsunori

WEKO 14159

Iijima, Katsunori

Search repository
内容記述(抄録)
内容記述タイプ Other
内容記述 Objective : We conducted a multicenter study in Akita Prefecture, Japan, to characterize the efficacy and safety of sofosbuvir (SOF) plus ribavirin (RBV) therapy in Japanese patients infected with hepatitis C virus (HCV) genotype 2.
Methods : All of the patients were infected with HCV genotype 2. Patients received 12 weeks of treatment with 400 mg of SOF daily plus weight-based RBV (600-1,000 mg daily).
Results : A total of 170 patients were enrolled in this study, and 167 patients were followed for 12 weeks after its completion. Among our patients, 28.2% (48/170) had liver cirrhosis (LC). Overall, 159 patients achieved a sustained virologic response for 12 weeks (SVR12), while 8 showed virologic failure. There were no significant differences in the rates of SVR12 between the chronic hepatitis (CH) and LC patients. No significant differences were noted between the CH and LC patients in the rates of any adverse events.
Conclusion : We found that SOF plus RBV treatment resulted in high rates of SVR12 with a favorable safety and tolerability profile, including patients with cirrhosis.
著者版フラグ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
書誌情報 秋田医学

巻 47, 号 1, p. 21-30, 発行日 2020-06-30
ISSN
収録物識別子タイプ ISSN
収録物識別子 0386-6106
NCID
収録物識別子タイプ NCID
収録物識別子 AN00009294
出版者
出版者 秋田医学会
戻る
0
views
See details
Views

Versions

Ver.1 2023-07-25 11:01:39.861717
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3